March 01, 2015 7:34 AM ET

Biotechnology

Company Overview of DynPort Vaccine Company LLC

Company Overview

DynPort Vaccine Company LLC provides biopharmaceutical product development programs for government agencies in the United States and internationally. It offers government contracting for business and biopharmaceutical product development, which include program management, risk identification and management, subcontracts management, and financial reporting; health and security protection services for the U.S. and allied governments in protecting soldiers and civilians against emerging diseases and possible bioterror threats; and infectious disease therapeutics. The company also provides consulting services to biotechnology and pharmaceutical companies. It serves government agencies, biotech c...

64 Thomas Johnson Drive

Frederick, MD 21702

United States

Founded in 1997

Phone:

301-607-5000

Fax:

301-607-5099

Key Executives for DynPort Vaccine Company LLC

President
Director of Finance
Associate Director of Communications
Contracts Director
Director of Program Management Office
Compensation as of Fiscal Year 2014.

DynPort Vaccine Company LLC Key Developments

DynPort Vaccine Company LLC Receives Follow-On Contract for Phase I Infectious Disease Trials

Computer Sciences Corporation announced that its company, DynPort Vaccine Company LLC received a follow-on contract to continue supporting the National Institute of Allergy and Infectious Diseases, or NIAID, part of the National Institutes of Health. Valued at up to $90 million, the award is a 10-year Indefinite Delivery/Indefinite Quantity contract to support and conduct Phase I clinical trials of infectious disease therapeutics. Under the agreement, DVC and its teaming partners, Quintiles, Health Decisions and WCCT Global, will support and manage Phase I clinical trial units to assess the safety of investigational therapeutic products being studied by NIAID, and determine pharmacokinetic and pharmacodynamic properties, which will inform appropriate human dosing regimens. As the prime contractor, DVC will manage the overall program and clinical operations, quality assurance and co-development of protocols and concepts. Quintiles, Health Decisions and WCCT Global will provide clinical research and support services for the implementation and conduct of approved clinical trial protocols. Trials will include therapeutic candidates for a broad range of infectious diseases, and investigational products tested will include those to protect against viral (other than HIV), bacterial, parasitic and fungal pathogens, including NIAID priority biodefense pathogens and emerging and re-emerging infectious diseases.

WCCT Global Announces as One of Three Supporting Clinical Research Partners for DynPort Vaccine Company Development

WCCT Global announced to be a strategic partner with Dynport Vaccine Company along with two other CROs for supporting clinical trials to evaluate Anti-Infective Drugs with the NIAID. This partnership is publicized just shortly after the strategic collaboration that was reached between WCCT Global and the NIAID for influenza challenge research. This agreement between DynPort and WCCT Global will be directed toward phase I support to demonstrate the safety of investigational therapeutic products being studied by the NIAID in order to provide data for appropriate human dosing in later phase development. The types of therapeutic agents that will be investigated include potential medications against bacterial, parasitic, and fungal pathogens.

DynPort Vaccine Company LLC Wins Contract Worth Up to $90 Million

CSC announced that its DynPort Vaccine Company LLC, received a follow-on contract to continue supporting the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. Valued at up to $90 million, the award is a 10-year Indefinite Delivery/Indefinite Quantity contract to support and conduct Phase 1 clinical trials of infectious disease therapeutics. Under the agreement, DVC and its teaming partners, Quintiles, Health Decisions and WCCT Global, will support and manage Phase 1 clinical trial units to assess the safety of investigational therapeutic products being studied by NIAID, and determine pharmacokinetic and pharmacodynamic properties, which will inform appropriate human dosing regimens. As the prime contractor, DVC will manage the overall program and clinical operations, quality assurance and co-development of protocols and concepts. Quintiles, Health Decisions and WCCT Global will provide clinical research and support services for the implementation and conduct of approved clinical trial protocols. Trials will include therapeutic candidates for a broad range of infectious diseases, and investigational products tested will include those to protect against viral (other than HIV), bacterial, parasitic and fungal pathogens, including NIAID priority biodefense pathogens and emerging and re-emerging infectious diseases.

Similar Private Companies By Industry

Company Name Region
Warner Instruments Corporation United States
Padlock Therapeutics, Inc. United States
Eureka Therapeutics, Inc. United States
Mesoblast, Inc. United States
Vedanta Biosciences, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DynPort Vaccine Company LLC, please visit www.csc.com/dvc. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.